These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18027213)

  • 1. Discussion of "The White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
    Hemmings R
    J Biopharm Stat; 2007; 17(6):1021-7; discussion 1029-32. PubMed ID: 18027213
    [No Abstract]   [Full Text] [Related]  

  • 2. Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
    Grieve AP
    J Biopharm Stat; 2007; 17(6):997-1004; discussion 1029-32. PubMed ID: 18027209
    [No Abstract]   [Full Text] [Related]  

  • 3. Discussion of the "White Paper of the PhRMA PISC Working Group on adaptive dose-ranging designs".
    Leonov S
    J Biopharm Stat; 2007; 17(6):1013-4; discussion 1029-32. PubMed ID: 18027211
    [No Abstract]   [Full Text] [Related]  

  • 4. Innovative approaches for designing and analyzing adaptive dose-ranging trials.
    Bornkamp B; Bretz F; Dmitrienko A; Enas G; Gaydos B; Hsu CH; König F; Krams M; Liu Q; Neuenschwander B; Parke T; Pinheiro J; Roy A; Sax R; Shen F
    J Biopharm Stat; 2007; 17(6):965-95. PubMed ID: 18027208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
    Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
    J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation and recommendations on adaptive dose-ranging trials: highlights from the PhRMA Adaptive Dose-Ranging Studies Working Group.
    Pinheiro J
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):47S-49S. PubMed ID: 20881216
    [No Abstract]   [Full Text] [Related]  

  • 7. Discussion of the paper "Adaptive dose-ranging designs".
    Burman CF
    J Biopharm Stat; 2007; 17(6):1005-11; discussion 1029-32. PubMed ID: 18027210
    [No Abstract]   [Full Text] [Related]  

  • 8. Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
    Wang SJ
    J Biopharm Stat; 2007; 17(6):1015-20; discussion 1029-32. PubMed ID: 18027212
    [No Abstract]   [Full Text] [Related]  

  • 9. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
    Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
    J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop.
    Krams M; Burman CF; Dragalin V; Gaydos B; Grieve AP; Pinheiro J; Maurer W; Gallo P
    J Biopharm Stat; 2007; 17(6):957-64. PubMed ID: 18027207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
    Chuang-Stein C; Beltangady M
    J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive designs for dose-finding studies based on sigmoid Emax model.
    Dragalin V; Hsuan F; Padmanabhan SK
    J Biopharm Stat; 2007; 17(6):1051-70. PubMed ID: 18027216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.
    Cheng B; Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1171-7. PubMed ID: 21058113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose finding designs for continuous responses and binary utility.
    Fedorov VV; Wu Y
    J Biopharm Stat; 2007; 17(6):1085-96. PubMed ID: 18027218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive modelling of dose-response relationships using smoothing splines.
    Kirby S; Colman P; Morris M
    Pharm Stat; 2009; 8(4):346-55. PubMed ID: 19205006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction to discussion papers on draft FDA guidance on adaptive designs.
    Chang M
    J Biopharm Stat; 2010 Nov; 20(6):1113-4. PubMed ID: 21058106
    [No Abstract]   [Full Text] [Related]  

  • 19. The final dose of clinical trial designs.
    Wyllie MG
    BJU Int; 2004 Oct; 94(6):929-30. PubMed ID: 15476538
    [No Abstract]   [Full Text] [Related]  

  • 20. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.